- Home
- ATYR vs TNGX Comparison
ATYR vs TNGX Comparison
Compare ATYR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- TNGX
- Stock Information
- Founded
- ATYR 2005
- TNGX 2014
- Country
- ATYR United States
- TNGX United States
- Employees
- ATYR N/A
- TNGX N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- TNGX Health Care
- Exchange
- ATYR Nasdaq
- TNGX Nasdaq
- Market Cap
- ATYR 330.7M
- TNGX 317.4M
- IPO Year
- ATYR 2015
- TNGX N/A
- Fundamental
- Price
- ATYR $4.32
- TNGX $2.36
- Analyst Decision
- ATYR Strong Buy
- TNGX Strong Buy
- Analyst Count
- ATYR 6
- TNGX 8
- Target Price
- ATYR $18.60
- TNGX $13.14
- AVG Volume (30 Days)
- ATYR 1.0M
- TNGX 574.3K
- Earning Date
- ATYR 03-13-2025
- TNGX 03-17-2025
- Dividend Yield
- ATYR N/A
- TNGX N/A
- EPS Growth
- ATYR N/A
- TNGX N/A
- EPS
- ATYR N/A
- TNGX N/A
- Revenue
- ATYR $235,000.00
- TNGX $43,383,000.00
- Revenue This Year
- ATYR N/A
- TNGX $27.73
- Revenue Next Year
- ATYR $1,299.74
- TNGX N/A
- P/E Ratio
- ATYR N/A
- TNGX N/A
- Revenue Growth
- ATYR N/A
- TNGX 15.67
- 52 Week Low
- ATYR $1.42
- TNGX $2.35
- 52 Week High
- ATYR $4.66
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ATYR 63.39
- TNGX 33.13
- Support Level
- ATYR $3.38
- TNGX $2.35
- Resistance Level
- ATYR $3.81
- TNGX $2.51
- Average True Range (ATR)
- ATYR 0.27
- TNGX 0.22
- MACD
- ATYR 0.06
- TNGX -0.04
- Stochastic Oscillator
- ATYR 74.44
- TNGX 0.94
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.